Christopher Tovey joins GW Pharmaceuticals

As chief operating officer

Chris Tovey

GW Pharmaceuticals, a developer of cannabinoid pharmaceutical products, has appointed Christopher Tovey to the newly created position of chief operating officer.

Tovey has spent more than 25 years in the pharmaceutical industry. He was most recently vice president of global marketing operations at UCB Pharmaceuticals.

Prior to joining UCB, Tovey was vice president, managing director UK and Ireland at Nabi Biopharmaceuticals, a US-based biopharmaceutical company. Before that he spent 18 years at GlaxoSmithKline in senior commercial roles in Europe and the UK.

Dr Geoffrey Guy, GW Pharmaceuticals’ chairman, said: ‘With multiple recent launches of Sativex, numerous additional launches planned, and major advances in our pipeline, GW’s operations have now expanded significantly. We are delighted to have attracted in Chris someone with extensive and diverse commercial experience across the pharmaceutical industry to perform the important role of chief operating officer.’

Companies